China Resources Boya Bio pharmaceutical Group Co Ltd - Asset Resilience Ratio
China Resources Boya Bio pharmaceutical Group Co Ltd (300294) has an Asset Resilience Ratio of 23.15% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check asset allocation strategy of China Resources Boya Bio pharmaceutical to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2025)
This chart shows how China Resources Boya Bio pharmaceutical Group Co Ltd's Asset Resilience Ratio has changed over time. See China Resources Boya Bio pharmaceutical (300294) net asset quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down China Resources Boya Bio pharmaceutical Group Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of China Resources Boya Bio pharmaceutical .
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥1.95 Billion | 23.15% |
| Total Liquid Assets | CN¥1.95 Billion | 23.15% |
Asset Resilience Insights
- Good Liquidity Position: China Resources Boya Bio pharmaceutical Group Co Ltd maintains a healthy 23.15% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
China Resources Boya Bio pharmaceutical Group Co Ltd Industry Peers by Asset Resilience Ratio
Compare China Resources Boya Bio pharmaceutical Group Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE |
Biotechnology | 84.34% |
|
3SBio Inc
F:83B |
Biotechnology | 10.64% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497 |
Biotechnology | 0.02% |
|
Novavax Inc
NASDAQ:NVAX |
Biotechnology | 53.87% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for China Resources Boya Bio pharmaceutical Group Co Ltd (2015–2025)
The table below shows the annual Asset Resilience Ratio data for China Resources Boya Bio pharmaceutical Group Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 30.79% | CN¥2.66 Billion ≈ $388.79 Million |
CN¥8.63 Billion ≈ $1.26 Billion |
+4.61pp |
| 2024-12-31 | 26.18% | CN¥2.20 Billion ≈ $321.80 Million |
CN¥8.40 Billion ≈ $1.23 Billion |
-16.77pp |
| 2023-12-31 | 42.95% | CN¥3.36 Billion ≈ $492.03 Million |
CN¥7.83 Billion ≈ $1.15 Billion |
+3.19pp |
| 2022-12-31 | 39.76% | CN¥3.19 Billion ≈ $467.37 Million |
CN¥8.03 Billion ≈ $1.18 Billion |
+4.33pp |
| 2021-12-31 | 35.42% | CN¥2.70 Billion ≈ $395.09 Million |
CN¥7.62 Billion ≈ $1.12 Billion |
+33.36pp |
| 2016-12-31 | 2.07% | CN¥50.00 Million ≈ $7.32 Million |
CN¥2.42 Billion ≈ $354.05 Million |
+1.15pp |
| 2015-12-31 | 0.91% | CN¥20.00 Million ≈ $2.93 Million |
CN¥2.19 Billion ≈ $320.20 Million |
-- |
About China Resources Boya Bio pharmaceutical Group Co Ltd
China Resources Boya Bio-pharmaceutical Group Co.,Ltd engages in the research, development, production, and sale of blood products in China. It offers blood products, such as human serum albumin; human, intravenous, freeze-dried intravenous, hepatitis B, tetanus, and rabies immunoglobulin; and human fibrinogen, prothrombin complex, and coagulation factor VIII. The company also provides compound b… Read more